Physician profile
Shi Yu
NPI 1750744967
$5,279.07
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $763 · 2021: $1,497 · 2022: $1,657 · 2023: $69.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $680.19 | 2019-2022 | |
| Amgen INC. | $530.08 | 2019-2022 | |
| Genzyme Corporation | $506.06 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $468.73 | 2019-2022 | |
| Celgene Corporation | $430.51 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $399.21 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $299.76 | 2022 | |
| Exelixis INC. | $259.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $212.42 | 2022 | |
| Incyte Corporation | $188.22 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.61 | 2021 | |
| Epizyme, INC. | $125.00 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $124.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.09 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $113.38 | 2019 | |
| Janssen Biotech, INC. | $99.95 | 2022 | |
| Astellas Pharma US INC | $86.98 | 2022-2023 | Padcev |
| Merck Sharp & Dohme LLC | $84.48 | 2022 | |
| Servier Pharmaceuticals LLC | $63.64 | 2022 | |
| Terumo Bct, INC. | $63.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $42.34 | 2022 | |
| Pfizer INC. | $33.08 | 2019 | |
| Daiichi Sankyo INC. | $24.87 | 2022 | |
| Eisai INC. | $23.89 | 2022 | |
| Glaxosmithkline, LLC. | $18.59 | 2021 | |
| Lilly USA, LLC | $18.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shi Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.